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2

taining l7B~estradiol or progesterone useful in the treat
ment of conditions such as menopause, menstrual disor
ders, etc. which are known to respond to administration

METHOD OF ADMINISTERING NATURAL .

FEMALE SEX HORMONES

of a natural or synthetic female sex hormone.

BACKGROUND OF
INVENTION
5
The foregoing objects are achieved by nasal adminis
tration of l7B-estradiol (if desired, in the form of one of
1. Field of the Invention
its estrogenically effective esters) and/or progesterone.
The present invention relates to a novel method of
administering the natural female sex hormones, 17/3- . According to the invention, these natural female sex
hormones are administered via a novel nasal dosage
estradiol and progesterone, and to novel dosage forms

containing those compounds, singly or in combination,

form, ‘ i.e., a solution, suspension, ointment or gel

which are adapted for nasal administration.

adapted for nasal administration.

2. Description of the Prior Art
l7B-estradiol is the most potent natural estrogen
found in human beings and is the major secretory prod
uct of the ovary. It is readily oxidized in the body to

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a semi-logarithmic plot of mean blood levels

of progesterone after intravenous (IV), nasal and in
traduodenal/oral (ID) administration of a close of 50 ug

estrone, which in turn can be hydrated to estriol. These

transformations take place mainly in the liver, where

of progesterone per rat.

there is free interconversion between estrone and estra
diol. All three of these natural estrogens are excreted in

FIG. 2 is a graph showing the area under the curve as‘
a function of dose for the intravenous (IV) and nasal

the urine as glucuronides and sulfates, along with ahost

, r

.

routes of progesterone administration (50 pg, 100' pg
and 150 [.tg dosage levels).
a
FIG. 3 is a semi-logarithmic plot of mean blood levels
of total unconjugated estrogens (TUE) following intra
venous (IV), nasal and intraduodenal/oral (ID) admin

of related, minor products in water-soluble complexes.
It is widely known that, following oral administration
of micronized l7,B-estradiol (E2), the incremental circu
lation estrogen is principally the less active species es
trone (E1), which reaches a peak concentration many

istration of a dose of 10 pg of l7B-est‘radiol per rat.

times greater than that of E2. The conversion of E2 to
FIG. 4 is a semi-logarithmic plot of mean blood levels
E1 and subsequently to other metabolites takes place
of estradiol (E2) following intravenous (IV), nasal and
during absorption from the intestine and passage
intraduodenal/oral (ID) administration of a dose of 10
through the liver. This extensive metabolism greatly
'
limits the oral effectiveness of the natural estrogens and 30 pg of l'ZB-estradiol per rat.
7 FIG. 5 is a semi-logarithmic plotof mean blood levels
their esters. Indeed, because of their limited oral ef?
, of estrone (E1 ) following intravenous (IV), nasal and
cacy, l7B-estradiol and its esters are generally adminis
intraduodenal/oral (ID) administration of a dose of 10
tered by intramuscular injection. '
pg of V17B~estradiol per rat.
Progesterone is the active natural progestin which
occurs in the corpus luteum, placenta and adrenal cor
DETAILED DESCRIPTION OF THE
tex. It is not effective by mouth because‘ of its rapid
INVENTION
'metabolism in the intestinal epithelium and in the liver,
The word “progesterone” as used herein means
and is therefore only administered intramuscularly.
pregn-4-ene-3,20-dione, i.e., the compound of the for
Because of their limited oral effectiveness, these natu
ral female sex hormones have not found utility in oral 40

mula

-

contraceptives. Instead, only active synthetic estrogens
and progestins have been prepared and are used for

CH 3

contraceptive purposes. The synthetic derivatives have

CO

also in many cases replaced the natural substances in the
treatment of menopause, threatened abortion, etc. How 45

ever, the synthetic derivatives are, generally speaking,
much more likely to cause toxic side effects than are the

relatively safe natural hormones._
SUMMARY OF THE INVENTION
In view of the foregoing, it is apparent that a serious

50'

need exists for the improved delivery of the natural
female sex hormones. Thus, it is an object of the present

and is intended to include progesterone derived from
natural sources as well as that made synthetically.

invention‘ to provide novel dosage forms and a novel

method of administering l7B-estradiol and progester

The word ‘.‘l7B-estradiol" as used herein is intended
55 to encompass any pharmaceutically acceptable, estro

one, separately or in combination, which will provide
greatly enhanced bioavailability as compared to oral
administration, while at the same time providing rela
tive ease of administration when compared to intramus—
cular injection.

O

genically active form of l7B-estradiol, i.e., estra
1,3,5(10)-triene-3,l7B-diol itself, which has the formula

-

It is a further object of the present invention to pro
vide a novel contraceptive method and novel composi
tions for accomplishing same which utilize the natural
female sex hormones, l7B-estradiol and progesterone,
and thus avoid'the disadvantages inherent in the use of 65

potentially unsafe synthetic estrogens and progestins.
It is yet a further object of the present invention to
provide a novel method and novel dosage forms con

HO
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and which may‘ be extracted from natural sources or

made synthetically, or one of its >3-_,or l7-monoesters or

3,'l7-dies_tlers. Byway of illustration, suitable esters of
17,8-est‘ra‘diol for purposes of the present invention in
clude 3-monoesters such as estradiol benzoate and'estra
diol 3-ace'tate; l7v-monoesters such as estradiol cypio

in bioavailability equal to only ‘1.2% that of an equiva
lent dose given ‘intravenously. Also from Table I, it can
be seen that the nasal bioavailability of progesterone at

nate,_estradi_ol l7épropionate,estrad‘iol ljv-aceta'te, estra

the 50 pg dosage level was 85.75 times greater than the

diol' 17-'heptanoatev (estradiol enanthate), estradiol 1']
undecanoate (elstradiolundecylat‘e) and estradiol l7-_val

oral bioavailability.

'

'

I

_

A

'

‘

'

-

the 50 pg dosage level, the peak plasma level was at
drops.

of dose for the intravenous and nasal routes. As can be
seen from FIG. 2, for both IV and nasal routes of ad
ministration the area under the curve (AUC) was di

rectly proportional to the dose administered.
' The'study described above indicates that progester
one is rapidly absorbed from the nasal mucosa into the

'Sprague-Dawley' male rats,‘- each weighing about 270
grams, were used in the progesterone study; For nasal

systemic :circulation without first pass metabolism. It is
further apparent from this study that the bioavailability

administration, the rats"were"anesthetized us'irigsodium
pentobarbital (50 mg/kg) an'd<the< drug was‘adrninis

of Japan, Okayama, April 1978,.except that the ‘end of
the tube leading from the esophagus _-to the nasal cavity

of progesterone when administered nasally is equivalent
"25

by the oral route.

"

(A study similar to ‘that described above was under
30

taken to' study the bioavailability of nasally adminis
tered 17,8-estradiol vis-a-vis its bioavailability via intra
venous and ‘oral routes. Sprague-Dawley male rats,

each weighing approximately 270 grams, were given
dosages of 5 pg, 10 pg and 20 pg/rat of [6,7-3H] 17B
estradiol in 0.1 in] isotonic saline containing 1% Tween
80 via the intravenous, nasal and intraduodenal routes,

oral (intraduodenal) administration, the rats were anes

thetized and the abdomen: of ‘each rat" wasl-opened
through a midline incision1'and‘a‘50 pg/rat dose of the

according to the procedures described above with re

d_rug;([4-14C]—progesterone in 01ml isotonic saline with
l'—2% Tween 80)__,Was .injected'idirecitly through the
were anesthetized and the drug was injected through
the femoral vein at dosage levels of 50 pg, 100 pg and

to, the bioavailability of the drug where administered

intravenously and vastly superior to'its bioavailability

.was closed and the drug was administered to the nostrils
which were then closed with anadhesive agent. For

duodenum. For intravenous administration, the) rats

‘

_ FIG. 2 shows the area under the curve as a function

‘

tered to thenasal cavity byrmeans ofia' micropip'et at
dosage levels of 50 pg, "100 pg and .1-50 pg/rat of [4
14C]-pr0gesterone- (.~8.51pCi/rat) in 0.1 ml of isotonic
saline-containing l—,2%. Tween" 80 as ‘a 'solubilizing
agent, according to the procedure described by Hirai-et
al, the 98th Annual Meeting of Pharmaceutical Society

~

tained in less than 7 minutes after instillation of the nose

these drugs when administered‘ orally' and‘ intrave
'

-

very rapidly absorbed from the nasal mucosa; thus, at

.

According to the present invention, it has surpris
ingly been found; that 17,8-estradiol and progesterone
can be administered nasally with results considerably
superior to those obtained 1with ioraladministration. The
following'studies' were unde’r'tak'e'n'i’to examine the bi
oavailability of progesterone and 17B-estradiol from
nasal solution in comparison with‘ the bioavailability of
nously.

1

. ': It can also be seen from FIG. 1 that progesterone is

erate; and 3,17-‘di'est‘ers such as est’radiol dipropionate
and estradiol diacetatelp

4

administration at each dosage were not significantly
different, even at the 0.001 level. However, as can be
seen from Table’ I,‘ oral administration vof 50 pg resulted

spect to ,the progesterone study. Blood samples were
40

taken periodically as described in the progesterone
Studyand assayed for estradiol (E2), estrone (E1) and

total ,unconjugated estrogens (TUE).
FIGS. 3, 4 and 5 show typical plots ofthe mean blood

150 pg/rat of [4"-l4C]-progesterone in 0.1 ml of isotonic
saline containing l—2% Tween 80. Blood was sampled

levels-of TUE, E2 and E1 following intravenous, nasal
and ‘oral administration of 10 pg of l7B-estradiol per

periodically from the femoral aorta after IV and nasal
administration, and lifrorn the tail vein after ID adminis
tration. Blood levels of progesterone were determined
by thin layer ch'romotograph-y.
.
FIG. 1 shows the mean blood levels of progesterone
for the study described above after intravenous, nasal
and oral administration of a dose of 50 pg/rat, while

rat. .These ?gures clearly show that l7B-estradiol is
rapidly absorbed by the nasal mucosa.
Table II below shows the area under the curve for the
three routes of administration at the various dosage

levels of 17,3-estradiol.

TABLE II

Table I below summarizes the area under the curve for

AREA UNDER THE CURVE AND BIOAVAILABILITY

the three-routes of administration-at the various doses.

. , ,.OF TUE, ‘E; AND E1 FOR THE DIFFERENT ROUTES
‘

‘

‘TABLET’

"

‘

_

OF ADIMINISTRATION AT THE VARIOUS DOSES

'

AREA UNDER THE CURVE AFTER INTRAVENOUS,

55

~ AUC()°° , nigilmiin/ml ‘-

Nasal

1V

Nasal

ID

IV

[V

50

1612.2“
i808

1659.0
i 109.2

19.0
1114.6

1.029

0.012

—

1.022

—

—

1,071

—

100

3520.0
i491.0

150

3599.0
.

5

‘ 1D

pg/rat

IV

.
'

'10-

4798.9

i4604

~i1885

‘mean t SE(r1 : 4-6).

By using the two tailed t-test, it canbe shown that the
area under the curve following intravenous and nasal

ORAL

-Iv
NASAL
.

-

.ORAL

65

v

‘

20
1

Iv
\

AUCQ‘”, NG. MIN. Mr‘
I TUE
555.5

.NASAL
,
»_

i62l.4

4480.2

ROU'I‘EOF

pG/RAT ADMINISTRATION

ADMINISTRATION
' NASAL AND
OFINTRAoUopENAL
PROGESTE'RONE IN RATS , ‘
Dose

DOSE

:

E1
53.4

146.8
(0.505)

33.5
(1.657)
10.6

119.2

11.1

(0.215)

(0.032) (0.199)

954.6
761.2

609.0
‘415.2

83.5
173.1

(0.797)

(0.682)

314.2

19.1

16.8

(0.329)

(0.031)

(0.201)

1936.9

NASAL“'

.1 ORAL

v337.0
(0.606)

E2
290.8

(2.073)

1062.6

164.4

891.8

354.0

(0.918)

(0.839)

(2.153)

786.9

53.4

42.4

1777.2

4,315,925
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AREA UNDER THE CURVE AND BIOAVAILABILITY

OF TUE, E; AND E] FOR THE DIFFERENT ROUTES
OF ADIMINISTRATION AT THEIVARIOUS DOSES
DOSE ROUTE OF
AUCQ°°,NG. MIN. ML-l

uG/RAT ADMINISTRATION,

TUE

E2

(0.400)

(0.050) (0.258)

6

tered contraceptive (analogous to “minipill" type of
oral contraceptives).
Suitable nontoxic pharmaceutically acceptable nasal

TABLE ll-continued

carriers for use in the compositions of the present inven
5 tion will be apparent to those skilled in the art of nasal

pharmaceutical formulations. For those not skilled in
the art, reference is made'to the text entitled “REM

13]

INGTON’S PHARMACEUTICAL SCIENCES”, 4th
edition, 1970. Obviously, the choice of suitable carriers

()RATlO VS. 1V

after nasal administration ranged from 60.6% to 91.8%

will depend on the exact nature of the particular nasal
dosage form desired, e.g. whether the active in

that of the corresponding doses given intravenously,

gredient(s) is/are to be formulated into a nasal solution

while oral administration resulted in TUE bioavailabil
ity that ranged from only 21.5% to 40.6% that of the

(for use as drops or as a spray), a nasal suspension, a
nasal ointment or a nasal gel, as well as on the identity

corresponding doses given intravenously. Thus, nasal

of the active ingredient(s). Preferred nasal dosage forms

bioavailability of TUE was from 2.26 to 2.83 times

are solutions, suspensions and gels, which contain a

greater than oral bioavailability. Even more signi?
cantly, Table II further shows that the E2 bioavailability
after nasal administration ranged from 50.5% to 83.9%

addition to the active ingredient(s). Minor amounts of

As can be seen from Table II, the TUE bioavailability

major amount of water (preferably puri?ed water) in

that of the corresponding doses given intravenously,

other ingredients such as pH adjusters (e.g., a base such
as NaOH), emulsi?ers or dispersing agents (e.g. poly

while oral administration resulted in E2 bioavailabilities
that ranged from only 3.1% to 5.0% that of the corre

oxyethylene 20 sorbitan mono-oleate), buffering agents,
preservatives, wetting agents and jelling agents (e.g.

sponding doses given intravenously. Thus, nasal bi

methylcellulose) may also be present. Also, a sustained

oavailability of E2 was from 13.23 to 21.74 times greater

release composition, e.g. sustained release gel, readily

than oral bioavailability.
The studies described above indicate that progester

relatively insoluble, long-acting forms, e.g. as estradiol

one and 17 B-estradiol are rapidly absorbed from the
nasal mucosa into systemic blood without extensive
intestinal or ?rst pass metabolism.

can be prepared by employing l7B-estradiol in one of its

cypionate.

Examples of the preparation of typical nasal composi:

nasal carrier therefor. As indicated earlier, any pharma
ceutically acceptable, estrogenically active form of

tions are set forth below. However, it is to be underi
stood that these examples are given by way of illustra
tion only and are not to be construed as limiting the
invention either in spirit or in scope as many modi?ca
tions both in materials and in methods will be apparent
35 to those skilled in the art.
EXAMPLE 1

l'lB-estradiol can be employed in the nasal form, e.g.,

25 milligrams of progesterone and 5v milligrams of

Progesterone and 17,8-estradiol can be conveniently
administered nasally to warm-blooded animals by for
mulating them, singly or in combination, into a nasal
dosage form comprising the selected natural female sex
hormone(s) and a nontoxic pharmaceutically acceptable

the'diol itself or one of its esters. In a preferred embodi
17,8-estradiol were combined with 10 milligrams of
ment of the invention, both progesterone and a suitable 40 Tween 80. That mixture was then combined. with a

form of 17/3-estradiol are present in the nasal dosage
form, which can be employed in preventing conception,
for example, by administration in a cyclic manner anala
gous to that used for the oral contraceptives.

In another embodiment, the estrogenic component, 45
i.e., one of the suitable forms of l7B-estradiol, is present

quantity of isotonic saline suf?cient to bring the total
volume to 50 milliliters. The solution was sterilized by

being passed through a 0.2 micron Millipore ?lter.
EXAMPLE 2

but progesterone is not; this type of composition may be

50 milligrams of progesterone and 5 milligrams of 17
B-estradiol were combined with 10 milligrams of

used for any of a variety of conditions for which natural

Tween 80. That mixture was then combined with a

or synthetic estrogens have previously been adminis
quantity of isotonic" saline sufficient to bring the total
tered, e. g., to control menopausal symptoms, hot flushes 50 volume of the solution to 50 milliliters. The solution was
sterilized by being passed through a 0.2 micron Mil
and later osteoporosis; also in atropic vaginitis, and to
lipore ?lter.
relieve postpartum breast engorgement, dysmenorrhea,
amenorrhea, menorrhagia, and as substitution therapy
EXAMPLE 3
in ovarian dwar?sm; also to control prostatic carci
noma, and possibly also as a “morning-after” contracep

250 milliliters of isotonic saline were heated to 80° C.

tive. Also, the “estrogen only” nasal composition could

and 1.50 grams of Methocel were added, with stirring.

be used in a sequential contraceptive regimen in which

The resultant mixture was allowed to stand at room

estrogen alone is to be administered for a part of the

temperature for 2 hours. Then, 50 milligrams of proges

cycle.

'‘

terone and 10 milligrams of l7B-estradiol were mixed
In another embodiment of the present invention, pro 60 together with 10 milligrams of Tween 80. The steroid/
gesterone is present in the nasal dosage form, but the
Tween mixture and a quantity of isotonic salinersuf?
estrogenic component is not. This type of composition
cient to bring the total 'volume to 500 milliliters were
may be used in the treatment of conditions for which
added to the gel and thoroughly mixed.

natural or synthetic progestins have previously been
used, e. g., in threatened or habitual abortion, endometri 65
osis and menstrual disorders such as dysmenorrhea and

functional uterine bleeding, in inhibiting ovulation and
possibly as a “progestin only" continuously adminis

EXAMPLE 4

Repetition of the procedure of Example 1, but omit
ting the 25 milligrams of progesterone, affords an “es

trogen only” nasal composition.

7
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pharmaceutically acceptable, estrogenically active form

EXAMPLE 5

of l7B-estradiol, together with a nontoxic pharmaceuti

Repetition of the procedure of Example 2, but omit
ting the 5 milligrams of l7B-estradiol, affords a “proges
terone only” nasal composition.

cally acceptable nasal carrier therefor.
5. A method according to claim 2 for eliciting a pro
gestational response in a mammal which comprises
nasally administering thereto a pharmaceutically ac
ceptable nasal dosage form which comprises a progesta

EXAMPLE 6
Substitution of an equivalent quantity of estradiol

tionally effective amount of progesterone and a non

benzoate, estradiol cypionate, estradiol dipropionate,

toxic pharmaceutically acceptable nasal carrier there

estradiol enanthate or estradiol l7-valerate for the 17,8

O for.

estradiol employed in Example 1, 2, 3 or 4 and repeti

6. A method according to claim 3 for eliciting an

tion of the procedures there detailed affords other nasal

estrogenic response in a mammal which comprises na

compositions according to the invention.

sally administering thereto a pharmaceutically accept
able nasal dosage form which comprises an estrogeni
cally effective amount of a pharmaceutically accept
able, estrogenically active form of l7B-estradiol and a
nontoxic pharmaceutically acceptable nasal carrier
therefor.

Naturally, the therapeutic dosage range for nasal
administration of the compositions of the present inven
tion will vary with the size of the patient, the condition
for which the composition is administered and the par
ticular form of l7B-estradiol employed (when the com
position is an “estrogen only” or estrogen/progestin

7. A method according to claim 1, 3, 4 or 6 wherein

combination). A typical dose ofa combination form for

the pharmaceutically acceptable, estrogenically active

use as a contraceptive would be from 10 pg to 500 pg of

form of 17B-estradiol is selected from the group consist
17/3-estradiol and from 10 pg to 5000 pg of progester
ing of 17,8-estradiol, 3~monoesters of 17,8-estradiol,
one, administered nasally once daily. The quantity of
l7-monoesters of l7B-estradiol and 3,17-diesters of 17,8
nasal dosage form needed to deliver the desired dose
estradiol.
will of course depend on ‘the concentration of the active 25
8. A method according to claim 7 wherein the phar

ingredients in the composition. For example, when a

maceutically acceptable, estrogenically active form of

composition as described in Example 2 above is used to
l7B-estradiol is l7B-estradiol.
deliver a typical dose of 0.5 mg of progesterone, the
9. A method according to claim 7 wherein the phar
volume of solution which would be needed would be
maceutically acceptable, estrogenically active form of
approximately 0.5 ml.
30 17,8-estradiol is estradiol benzoate.
While the invention has been described in terms of
10. A method according to claim 7 wherein the phar

various preferred embodiments, the skilled artisan will

maceutically acceptable, estrogenically active form of
17,8-estradiol is estradiol cypionate.

appreciate that various modi?cations, substitutions,
omissions and additions may be made without departing

from the spirit thereof. Accordingly, it is intended that
the scope of the present invention be limited solely by
the scope of the following claims.

11. A method according to claim 7 wherein the phar
35

maceutically acceptable, estrogenically active form of
l7B-estradiol is estradiol dipropionate.

12. A method according to claim 7 wherein the phar
What is claimed is:
maceutically acceptable, estrogenically active form of
1. A method of mammalian contraception which
l7B-estradiol is estradiol enanthate.
comprises nasally administering to a female mammal a 40
13. A method according to claim 7 wherein the phar
contraceptively effective amount of a combination of
maceutically acceptable, estrogenically active form of
progesterone and a pharmaceutically acceptable, estro
l7B-estradiol is estradiol l7-valerate.
genically active form of 17,8-estradiol.
14. A method according to claim 4, 5 or 6 wherein
2. A method of eliciting a progestational response in
said dosage form is a nasal solution.
a mammal which comprises nasally administering 45
15. A method according to claim 4, 5 or 6 wherein
thereto a progestationally effective amount of proges
said dosage form is a nasal suspension.
terone.
16. A method according to claim 4, 5 or 6 wherein
3. A method of eliciting an estrogenic response in a
said dosage form is a nasal ointment.
mammal which comprises nasally administering thereto
17. A method according to claim 4, 5 or 6 wherein
an estrogenically effective amount of a pharmaceuti
said dosage form is a nasal gel.

cally acceptable, estrogenically active form of 178

18. A method according to claim 4 or 6 wherein said

estradiol.

dosage form is a sustained release nasal dosage form.

4. A method of mammalian contraception according
to claim 1 which comprises nasally administering to a
female mammal a pharmaceutically acceptable nasal

19. A method according to claim 4 or 6 wherein said
dosage form is a sustained release nasal gel.
20. A method according to claim 4, 5 or 6 wherein
said dosage form is isotonic.

dosage form which comprises a contraceptively effec
tive amount of a combination of progesterone and a

*

65
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